Skip to content
Triangle logo TriangleGet started
← Study library

NCT00103259 · REGISTRY CONDITION SEARCH

Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2014-05-23

This randomized phase II trial is studying bortezomib and irinotecan to see how well they work compared to bortezomib alone in treating patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with irinotecan may kill more tumor cells. It is not yet known whether giving bortezomib together with irinotecan is more effective than bortezomib alone in treating head and neck cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Response Rate on Step 1

→

outcome · POSTED

Response Rate on Step 2

→

outcome · POSTED

Progression-free Survival on Step 1

→

outcome · POSTED

Overall Survival on Step 1

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients may have had one (0-1) prior chemotherapy regimen for recurrent or metastatic SCCHN; chemotherapy for recurrent or metastatic disease must have been completed at least 4 weeks prior to study entry * Patients must not have been previously treated with irinotecan or bortezomib * Patients must not be receiving radiation treatment * Patients must have histologically confirmed squamous cell carcinoma of the head and neck * Patients must have biopsy for histological confirmation of recurrent or metastatic disease if disease is now recurrent or metastatic after prior disease free-interval * NOTE: If patient has had a complete response (of any duration) but now has suspected recurrent disease (regardless of the time interval), the patient will need a biopsy for confirmation of SCCHN * Disease must not be amenable to potentially curative local therapies or patient must have refused such options * Patients must not have nasopharyngeal subtypes WHO II or III. Patients may have nasopharyngeal WHO I; salivary gland primaries are excluded from study SUBTYPES OF NASOPHARYNGEAL CARCINOMA (NPC) WHO type 1 - keratinizing SCC WHO type 2 - nonkeratinizing epidermoid carcinoma WHO type 3 - undifferentiated carcinoma * Patients must have measurable disease * Baseline measurements and evaluations must be obtained within 4 weeks of registration to the study * Measurable disease limited to a pre-irradiated location must be biopsy proven to be squamous cell carcinoma * Must have at least one objective measurable disease parameter; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; all areas of disease should be recorded and mapped out in order to assess response and uniformity of response to therapy * Radiographic findings are acceptable providing that clear-cut measurement can be made * Measurable disease limited to a pre-irradiated location must be biopsy-proven to be squamous cell carcinoma * Patients must have ECOG performance status 0 or 1 * Patients must not have grade 2 or higher peripheral neuropathy within 2 weeks of study entry * Leukocytes \>= 3,000/uL * Absolute neutrophil count \>= 1,500/uL * Platelets \>= 100,000/uL * Total bilirubin within normal institutional limits * AST(SGOT) and ALT(SGPT) =\< 2.5 x institutional upper limit of normal * Creatinine within normal institutional limits OR * Creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * Patients must have had no prior invasive malignancy unless the disease-free interval is 5 years or more * Women must not be pregnant or breast-feeding due to the fact that the teratogenic or abortifacient effects of PS-341are unknown; the effect of PS-341 on the nursing infant are also unknown; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy * Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Patients with known brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events * Patients must not have history of allergic reactions to PS-341 or allergic reaction attributed to compounds of similar chemical or biologic composition to PS-341 including boron or mannitol * Patients must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements * ELIGIBILITY FOR RE-REGISTRATION TO ARM A (FOR ARM B PATIENTS AT THE TIME OF PROGRESSION * Patients must have ECOG performance status 0 or 1 * Leukocytes \>= 3,000/uL * Absolute neutrophil count \>- 1,500/uL * Platelets \>= 100,000/uL * Total bilirubin within normal institutional limits * AST(SGOT) and ALT(SGPT) =\< 2.5 x institutional upper limit of normal * Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * Patients with known brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
    intervention Names
    1. Drug: bortezomib
    2. Drug: irinotecan hydrochloride
    3. Other: laboratory biomarker analysis
    label
    Arm I (bortezomib, irinotecan hydrochloride)
    type
    EXPERIMENTAL
  2. description
    Patients receive bortezomib as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may cross over to arm I.
    intervention Names
    1. Drug: bortezomib
    2. Other: laboratory biomarker analysis
    label
    Arm II (bortezomib)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm I (bortezomib, irinotecan hydrochloride)
    2. Arm II (bortezomib)
    description
    Given IV
    name
    bortezomib
    other Names
    1. LDP 341
    2. MLN341
    3. VELCADE
    type
    DRUG
  2. arm Group Labels
    1. Arm I (bortezomib, irinotecan hydrochloride)
    description
    Given IV
    name
    irinotecan hydrochloride
    other Names
    1. Campto
    2. Camptosar
    3. CPT-11
    4. irinotecan
    5. U-101440E
    type
    DRUG
  3. arm Group Labels
    1. Arm I (bortezomib, irinotecan hydrochloride)
    2. Arm II (bortezomib)
    description
    Optional correlative studies
    name
    laboratory biomarker analysis
    type
    OTHER
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
DOUBLE
who Masked
  1. PARTICIPANT
  2. INVESTIGATOR
primary Purpose
TREATMENT
Enrollment
count
71
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Tumor response was evaluated via Response Evaluation Criteria In Solid Tumors (RECIST) v1.0, and response rate was defined as the proportion of patients with a complete response or partial response among all eligible and treated patients. Complete response was defined as disappearance of all tumor lesions. Partial response was defined as at least a 30% decrease in the sum of the longest diameters of target lesions.
    measure
    Response Rate on Step 1
    time Frame
    Tumor response was assessed every 2 cycles until progression or intolerable toxicity with maximum of 3 years
secondary Outcomes
  1. description
    Tumor response was evaluated via Response Evaluation Criteria In Solid Tumors (RECIST) v1.0, and response rate was defined as the proportion of patients with a complete response or partial response among all eligible and treated patients. Complete response was defined as disappearance of all tumor lesions. Partial response was defined as at least a 30% decrease in the sum of the longest diameters of target lesions.
    measure
    Response Rate on Step 2
    time Frame
    Tumor response was assessed after every 2 cycles until progression or intolerable toxicity with maximum of 3 years
  2. description
    Progression-free survival was defined as time from registration to step 1 to disease recurrence or death from any cause, whichever occurred first. Disease progression was measured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.0, and defined as at least a 20% increase in the sum of the longest diameters of target lesions.
    measure
    Progression-free Survival on Step 1
    time Frame
    Every 3 months for first 2 years from protocol entry, then every 6 months until 3 years from study entry
  3. description
    Overall survival was defined as time from registration on step 1 to death from any cause. It was evaluated in all 61 eligible and treated patients.
    measure
    Overall Survival on Step 1
    time Frame
    Survival was assessed every 3 month within 2 years and every 6 months betwen 2 and 3 years
Full study description
brief Summary
This randomized phase II trial is studying bortezomib and irinotecan to see how well they work compared to bortezomib alone in treating patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with irinotecan may kill more tumor cells. It is not yet known whether giving bortezomib together with irinotecan is more effective than bortezomib alone in treating head and neck cancer.
detailed Description
PRIMARY OBJECTIVES: I. To evaluate the activity of combination of PS-341 (bortezomib) and irinotecan in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) and the response rate of single agent PS-341 (followed by irinotecan at time of progression). SECONDARY OBJECTIVES: I. To continue exploring the toxicity of PS-341 alone and the combination of PS-341 and irinotecan in this patient population. II. To evaluate time to progression, overall survival and response to irinotecan and PS-341 when given after PS-341 alone. III. To evaluate the relationship between pre-treatment nuclear localization of NF-kB, and NF-kB regulated gene expression in tissue (Cyclin D1, IAP1, Bcl-XL, Topo I), and serum (IL-6, IL-8, GRO-1 and VEGF) and response. OUTLINE: Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Arm II: Patients receive bortezomib as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may cross over to arm I. Patients are followed every 3-6 months for up to 3 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-63d6c6952b16d57118b1
      requested nct id
      NCT00103259
      primary nct id
      NCT00103259
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      payload sha256
      47425ec2d543eecf43e97e175117b21260188a2a806c258f2f5eb18731ac8a66
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-63d6c6952b16d57118b1
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00103259
      occurrences
      1. context exact
        NCT00103259
        end
        11
        exact text
        NCT00103259
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hypopharyngeal Cancer
      query disease state id
      ds-hypopharyngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      source json pointer
      /studies/18/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      4df20eb2a0d91177fa4c75e65c0c7c952ad711f60723e9a73f594dcda6a9240d
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-f6143e67bfc7d5bf7c9d
      requested nct id
      NCT00103259
      primary nct id
      NCT00103259
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      payload sha256
      15f18c4256244c27598ed875db3626adea3ea2ed490534b4ae54cafca63f0b64
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-f6143e67bfc7d5bf7c9d
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00103259
      occurrences
      1. context exact
        NCT00103259
        end
        11
        exact text
        NCT00103259
        start
        0
      offset unit
      unicode_code_points
      query cond
      Laryngeal Cancer
      query disease state id
      ds-laryngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      source json pointer
      /studies/28/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      4df20eb2a0d91177fa4c75e65c0c7c952ad711f60723e9a73f594dcda6a9240d

    Preserved source evidence · Not medical advice